Grant: Doctoral Research Award: Canada Graduate Scholarships
University of Toronto
$105,000.00
Development and Translation of Fluorine-18 Radiolabeled ALK2 Inhibitors for Positron Emission Tomography Imaging in Diffuse Intrinsic Pontine Glioma
FY 2022-23
Summary
Diffuse intrinsic pontine glioma (DIPG) is a rare childhood cancer that affects part of the brainstem. DIPG is typically diagnosed in children aged 5-10 years old and does not have any effective forms of treatment. Since there are no treatments, the average survival time for children who are diagnosed with DIPG is only 11 months and the number of children who survive up to 2 years is less than 10%. We are a part of a global, open science initiative to find effective treatments for children suffering from DIPG. One drug target of interest is an enzyme (ALK2) that has a mutation associated with 25% of DIPG cases. The goal of this proposal is to develop a medical imaging tool that can be used by any hospital to image DIPG tumours in living patients for the first time. An imaging agent for ALK2 would be helpful for pediatric oncologists and scientists to study the role of ALK2 in the formation and growth of these deadly tumours. It could also help scientists determine if drugs that inhibit ALK2 activity could treat DIPG by stopping or reversing tumour growth. Creating a medical imaging agent for ALK2 in DIPG that is accessible to all hospitals could help develop effective treatments for this rare childhood cancer and improve the standard of care for these children.
Department
Program
Doctoral Research Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
475580
Name
Chasse Melissa
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Development and Translation of Fluorine-18 Radiolabeled ALK2 Inhibitors for Positron Emission Tomography Imaging in Diffuse Intrinsic Pontine Glioma
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Biomarkers; Brain Cancer; Diffuse Intrinsic Pontine Glioma; Drug Development; Positron Emission Tomography; Radiopharmaceutical
Abstract
Diffuse intrinsic pontine glioma (DIPG) is a rare childhood cancer that affects part of the brainstem. DIPG is typically diagnosed in children aged 5-10 years old and does not have any effective forms of treatment. Since there are no treatments, the average survival time for children who are diagnosed with DIPG is only 11 months and the number of children who survive up to 2 years is less than 10%. We are a part of a global, open science initiative to find effective treatments for children suffering from DIPG. One drug target of interest is an enzyme (ALK2) that has a mutation associated with 25% of DIPG cases. The goal of this proposal is to develop a medical imaging tool that can be used by any hospital to image DIPG tumours in living patients for the first time. An imaging agent for ALK2 would be helpful for pediatric oncologists and scientists to study the role of ALK2 in the formation and growth of these deadly tumours. It could also help scientists determine if drugs that inhibit ALK2 activity could treat DIPG by stopping or reversing tumour growth. Creating a medical imaging agent for ALK2 in DIPG that is accessible to all hospitals could help develop effective treatments for this rare childhood cancer and improve the standard of care for these children.
Competitiondate
202211
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Chasse, Melissa
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~